eli lilly glp-1 agonist Lilly's KwikPen Delivers Month of Zepbound in One Device Eli Lilly's oral GLP-1 pill

Description

In patients with CKD who are at increased risk for cardiovascular events, use of a GLP-1 RA may reduce the risk of progression of albuminuria, cardiovascular events, or both

Its important to note that the participants were enrolled in the 52-week extension phase from September 2019 to April 2020

Unregulated compounded GLP-1 products carry serious safety concerns because they are not reviewed or approved by the FDA for safety, effectiveness, or quality

4, Supplementary Table 1)

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)